INVIMA medical device approval in Colombia typically ranges from 3 to 12 months, depending on the device class and type of approval (sanitary registration vs. clinical trial permit). bioaccess® can accelerate this timeline by up to 40%.
The Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) is Colombia's national regulatory agency responsible for overseeing the approval and surveillance of medical devices. Understanding the INVIMA approval timeline is crucial for manufacturers seeking to introduce their devices into the Colombian market or conduct clinical trials.
The timeline for INVIMA medical device registration and INVIMA clinical trial approval is influenced by several factors, including the device's risk class (Class I, IIa, IIb, III) and whether the application is for full sanitary registration (Registro Sanitario) or a Clinical Trial Permit (Permiso Ético y Científico - PEC).
bioaccess® specializes in navigating these complex regulatory landscapes, leveraging its 10 countries presence and 200+ PIs network to expedite approvals. Our expertise allows us to achieve Colombia medical device approval 40% faster than traditional CROs, significantly reducing time to market and patient recruitment.
Sanitary registration is required for all medical devices to be commercialized in Colombia. The timelines vary based on the device's risk classification, as defined by INVIMA regulations, which align with GHTF (Global Harmonization Task Force) principles.
| Device Class | Description | INVIMA Estimated Timeline (Months) |
|---|---|---|
| Class I | Low risk (e.g., stethoscopes, bandages) | 3 - 6 |
| Class IIa | Moderate-low risk (e.g., catheters, needles) | 4 - 8 |
| Class IIb | Moderate-high risk (e.g., ventilators, infusion pumps) | 6 - 10 |
| Class III | High risk (e.g., implants, pacemakers) | 8 - 12+ |
These timelines are estimates and can be impacted by the completeness of the submission and INVIMA's review workload. Expedited pathways may exist for certain innovative or public health devices, but these are rare and require specific justification.
For medical devices undergoing clinical investigation in human subjects, a Clinical Trial Permit (Permiso Ético y Científico - PEC) from INVIMA is mandatory. This process runs concurrently with, or often precedes, full sanitary registration, especially for novel devices. The PEC ensures that the trial design, ethical considerations, and patient safety protocols meet INVIMA's stringent requirements, which are largely harmonized with international standards such like ICH GCP. The FDA and other international regulators like ANVISA and COFEPRIS share similar stringent requirements for clinical trial approval.
Typically, the INVIMA PEC approval process can take 4 to 8 months for all device classes, assuming a complete and high-quality submission. This period includes both ethical committee review (which often occurs in parallel) and INVIMA's scientific and regulatory assessment. Devices with higher risk classifications or novel technologies may require more extensive review, potentially extending this timeline.
The documentation required for both sanitary registration and clinical trial permits is extensive and must comply with INVIMA Decree 4725 of 2005 (for sanitary registration) and Resolution 8430 of 1993 (for clinical trials, though new regulations are pending). Key documents generally include:
The precision and completeness of this documentation are paramount. Any deficiencies can lead to significant delays, necessitating resubmissions and extending the overall INVIMA approval timeline.
Several factors can cause delays in the INVIMA medical device registration and PEC application processes:
Colombia medical device approval.bioaccess® mitigates these delays by:
INVIMA clinical trial approval is streamlined.With over 50+ clients and a track record of achieving FIH starts in 6-8 weeks across 10 countries, bioaccess® consistently delivers approvals that are 40% faster than typical US/EU timelines, with a 30% lower per-patient cost. This efficiency is critical for sponsors aiming for rapid market entry and patient access in Latin America.
INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) is Colombia's regulatory authority responsible for ensuring the safety, efficacy, and quality of medical devices. It oversees the processes for sanitary registration, which permits commercialization, and the Clinical Trial Permit (Permiso Ético y Científico - PEC), which allows for human clinical investigations. INVIMA's regulations align with international best practices like those from the FDA and ICH.
For a Class III medical device, which is considered high-risk, the INVIMA sanitary registration process can typically take between 8 to 12 months, or potentially longer. This extended timeline is due to the comprehensive review required for complex devices, necessitating extensive technical documentation, risk assessments, and clinical data. Precision in documentation is key to avoiding delays.
A Clinical Trial Permit (PEC) is distinct from sanitary registration because it specifically authorizes the conduct of clinical investigations involving human subjects, focusing on ethical considerations and patient safety within the research context. Sanitary registration, conversely, is for the commercialization of a device once its safety and efficacy are established for its intended use. Both are essential steps depending on the device's stage of development.
Yes, INVIMA generally recognizes and requires international quality system certifications such as ISO 13485 for medical device manufacturers. Providing a valid ISO 13485 certificate is a critical component of the submission package for both sanitary registration and Clinical Trial Permits, demonstrating adherence to international quality management standards and facilitating the approval process. Regulators like ANMAT and COFEPRIS have similar requirements.
bioaccess® accelerates INVIMA approval timelines by up to 40% through a combination of deep local regulatory expertise, meticulous pre-submission reviews of documentation, and proactive engagement with INVIMA and ethical committees. Our established processes, gained from managing 50+ clients and 200+ PIs across 10 countries, minimize common delays like incomplete submissions and ensure adherence to INVIMA's precise requirements, enabling 6-8 week FIH starts.